OncoSenX

OncoSenX is a late-stage preclinical cancer company. OncoSenX utilizes a unique lipid nanoparticle and plasmid DNA to target solid tumors based on transcriptional activity. OncoSenX's next-generation cancer therapy is more targeted and has fewer side effects. OncoSenX believes the fight against cancer should be conducted in conjunction with genetic information. OncoSenX's treatment offers a straightforward procedure that induces apoptosis in cancer cells.